PubMed Health⌕ Search

PubMed · 11877997

Temperature fields during the development of autoignition in a rapid compression machine.

Abstract

Temperature and concentration fields have been investigated in the cylindrical combustion chamber of a rapid compression machine (RCM) by schlieren photography, chemiluminescent imaging and planar laser induced fluorescence of acetone and of formaldehyde in a 2-dimensional sheet across the diameter. The timescale of particular interest was up to 10 ms after the piston has stopped. Experiments were performed in non-reactive and reactive conditions. Acetone was seeded in non-reactive mixtures. Combustion was studied first in a system containing di-tert-butyl peroxide vapour in the presence of oxygen. The decomposition of di-tert-butyl peroxide generates methyl radicals, which are then oxidised if oxygen is present. The overall reaction is exothermic and is characteristic of a conventional thermal ignition. In addition, chemiluminescence, resulting from CH2O*, accompanies the oxidation process. The combustion of n-pentane was then investigated at compressed gas temperatures that spanned the range in which there is a negative temperature dependence of the overall reaction rate, typically 750-850 K. The response to thermal feedback in this more complex thermokinetic system can be the opposite of the "thermal runaway" that accompanies di-tert-butyl peroxide combustion. The purpose of making comparisons between these two types of systems was to show how the temperature field generated in the RCM is modified in different ways by the interaction with the chemistry and to discuss the implications of this for the spatial development of spontaneous ignition. As the piston of the RCM moves it shears gas off the walls of the chamber. This probably creates a roll-up vortex, but more importantly it also collects gas from the walls and moves it across the cylinder head pushing it forward into a plug at the centre. Thus, soon after the end of compression there is an adiabatically heated gas which extends virtually to the wall, but this incorporates a plug of colder gas at its core. Diffusive transport will occur, but the timescale is relatively slow, and the effect hardly shows until at least 10 ms post-compression. The consequence of "thermal runaway" on a timescale that is compatible with the development of this temperature field is that the reaction rate in the adiabatically compressed toroidal region accelerates faster than in the core, and goes to completion first. A somewhat similar pattern emerges during n-pentane combustion when the initial condition is set at the lower end of the negative temperature dependent range. By contrast, at adiabatically compressed gas temperatures close to the upper end of the negative temperature dependent region, the reaction rate in the cooler core develops faster than that in the surrounding zone, and the temperature difference is rapidly smoothed out. This does not lead to spatial homogeneity in all respects, however, because different rates and extents of reaction generate different concentrations of intermediates. This stratification has implications for the eventual spatial evolution of spontaneous ignition.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J F Griffiths, J P MacNamara, C Mohamed, B J Whitaker, J Pan, C G Sheppard. 2001. Temperature fields during the development of autoignition in a rapid compression machine.. https://pubmed.ncbi.nlm.nih.gov/11877997/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗